{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:06:59Z","timestamp":1787497619108,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40264-017-0532-3","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T01:25:10Z","timestamp":1492392310000},"page":"693-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adjuvanted (AS03) A\/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt"],"prefix":"10.1007","volume":"40","author":[{"given":"Ga\u00ebl","family":"Dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry A.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bauchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique M.","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cohet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"532_CR1","first-page":"400","volume":"58","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","unstructured":"Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children\u2014Southern California, March\u2013April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"532_CR2","unstructured":"World Health Organization. World now at the start of 2009 influenza pandemic. http:\/\/www.who.int\/mediacentre\/news\/statements\/2009\/h1n1_pandemic_phase6_20090611\/en\/index.html . Accessed 1 Apr 2012."},{"key":"532_CR3","unstructured":"European Medicines Agency. Authorisation procedures. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/q_and_a\/q_and_a_detail_000080.jsp . Accessed 9 Apr 2016."},{"key":"532_CR4","unstructured":"European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Revision 1.1. EMEA\/359381\/2009 2009."},{"key":"532_CR5","unstructured":"European Medicines Agency. Pandemic report and lessons learned outcome of the European Medicines Agency\u2019s activities during the 2009 (H1N1) flu pandemic. EMA\/221017\/2011."},{"key":"532_CR6","unstructured":"Public Health Agency of Canada. Archived. Lessons learned review: Public Health Agency of Canada and Health Canada Response to the 2009 H1N1 pandemic\u2014Public Health Agency of Canada 2010. http:\/\/www.phac-aspc.gc.ca\/about_apropos\/evaluation\/reports-rapports\/2010-2011\/h1n1\/f-c-vaccin-eng.php . Accessed 16 Jun 2016."},{"key":"532_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1128\/CMR.16.3.357-364.2003","volume":"16","author":"A Duchini","year":"2003","unstructured":"Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16:357\u201364.","journal-title":"Clin Microbiol Rev"},{"key":"532_CR8","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1111\/j.1600-6143.2011.03753.x","volume":"11","author":"D Kumar","year":"2011","unstructured":"Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, Ison MG, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020\u201330.","journal-title":"Am J Transplant."},{"key":"532_CR9","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1111\/j.1600-6143.2011.03743.x","volume":"11","author":"SA Schaffer","year":"2011","unstructured":"Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant. 2011;11:2751\u20134.","journal-title":"Am J Transplant."},{"key":"532_CR10","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","volume":"10","author":"DW Vaughn","year":"2014","unstructured":"Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, et al. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. Hum Vaccin Immunother. 2014;10:2942\u201357.","journal-title":"Hum Vaccin Immunother."},{"key":"532_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pds.3918","volume":"25","author":"O Mahaux","year":"2016","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215\u201322.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"532_CR12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461\u201373.","journal-title":"Vaccine."},{"key":"532_CR13","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/jat.3130","volume":"35","author":"L Segal","year":"2015","unstructured":"Segal L, Wouters S, Morelle D, Gautier G, Le Gal J, Martin T, et al. Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. J Appl Toxicol. 2015;35:1564\u201376.","journal-title":"J Appl Toxicol."},{"key":"532_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.3328","volume":"17","author":"O Sobolev","year":"2016","unstructured":"Sobolev O, Binda E, O\u2019Farrell S, Lorenc A, Pradines J, Huang Y, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016;17:204\u201313.","journal-title":"Nat Immunol."},{"key":"532_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ndt\/gfr278","volume":"27","author":"S Brakemeier","year":"2012","unstructured":"Brakemeier S, Schweiger B, Lachmann N, Glander P, Sch\u00f6nemann C, Diekmann F, et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(\u00ae)) in renal transplant recipients. Nephrol Dial Transplant. 2012;27:423\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"532_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/j.1600-6143.2011.03604.x","volume":"11","author":"I Katerinis","year":"2011","unstructured":"Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, van Delden C, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011;11:1727\u201333.","journal-title":"Am J Transplant."},{"key":"532_CR17","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/j.1432-2277.2010.01193.x","volume":"24","author":"F Vistoli","year":"2011","unstructured":"Vistoli F, Fabio V, Focosi D, Daniele F, De Donno M, Monica DD, et al. Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: a report of two cases. Transplant Int. 2011;24:e28\u20139.","journal-title":"Transplant Int."},{"key":"532_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.healun.2011.01.707","volume":"30","author":"MM Schuurmans","year":"2011","unstructured":"Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant. 2011;30:685\u201390.","journal-title":"J Heart Lung Transplant."},{"key":"532_CR19","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2215\/CJN.04670511","volume":"6","author":"NE Broeders","year":"2011","unstructured":"Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racap\u00e9 J, Gastaldello K, et al. Influenza A\/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol. 2011;6:2573\u20138.","journal-title":"Clin J Am Soc Nephrol."},{"key":"532_CR20","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.2215\/CJN.02160311","volume":"6","author":"M Crespo","year":"2011","unstructured":"Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C, et al. Efficacy of influenza A H1N1\/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol. 2011;6:2208\u201314.","journal-title":"Clin J Am Soc Nephrol."},{"key":"532_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jpeds.2010.10.034","volume":"158","author":"I Goldschmidt","year":"2011","unstructured":"Goldschmidt I, Pfister ED, Becker M, H\u00e4ckl S, Bott OJ, Baumann U, et al. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J Pediatr. 2011;158:329\u201333.","journal-title":"J Pediatr."},{"key":"532_CR22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1399-3046.2010.01433.x","volume":"15","author":"L Altamirano-Diaz","year":"2011","unstructured":"Altamirano-Diaz L, West L, Humar A, Ely L, Urschel S, Gubbay J, et al. Early post-transplant vaccination with pandemic influenza A\/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant. 2011;15:172\u20135.","journal-title":"Pediatr Transplant."},{"key":"532_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/TP.0b013e3182115be0","volume":"91","author":"S Meyer","year":"2011","unstructured":"Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C, Sattinger E, et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation. 2011;91:1031\u20135.","journal-title":"Transplantation"},{"key":"532_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3851\/IMP2103","volume":"17","author":"C-A Siegrist","year":"2012","unstructured":"Siegrist C-A, Ambrosioni J, Bel M, Combescure C, Hadaya K, Martin P-Y, et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther (Lond). 2012;17:893\u2013903.","journal-title":"Antivir Ther (Lond)."},{"key":"532_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MOT.0b013e3283592622","volume":"17","author":"E Cordero","year":"2012","unstructured":"Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012;17:601\u20138.","journal-title":"Curr Opin Organ Transplant."},{"key":"532_CR26","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/infdis\/jis487","volume":"206","author":"CR Beck","year":"2012","unstructured":"Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250\u20139.","journal-title":"J Infect Dis."},{"key":"532_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/QCO.0b013e328355a79b","volume":"25","author":"RK Avery","year":"2012","unstructured":"Avery RK. Influenza vaccines in the setting of solid-organ transplantation: are they safe? Curr Opin Infect Dis. 2012;25:464\u20138.","journal-title":"Curr Opin Infect Dis."},{"key":"532_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion). Am Stat. 1999;53:177\u2013202.","journal-title":"Am Stat."},{"key":"532_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/2042098611435911","volume":"3","author":"T Williams","year":"2012","unstructured":"Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89\u201399.","journal-title":"Ther Adv Drug Saf."},{"key":"532_CR30","doi-asserted-by":"publisher","first-page":"e7594","DOI":"10.1136\/bmj.e7594","volume":"345","author":"L Arnheim-Dahlstr\u00f6m","year":"2012","unstructured":"Arnheim-Dahlstr\u00f6m L, H\u00e4llgren J, Weibull CE, Spar\u00e9n P. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ. 2012;345:e7594.","journal-title":"BMJ."},{"key":"532_CR31","doi-asserted-by":"publisher","first-page":"e009264","DOI":"10.1136\/bmjopen-2015-009264","volume":"6","author":"C Cohet","year":"2016","unstructured":"Cohet C, Haguinet F, Dos Santos G, Webb D, Logie J, Lc Ferreira G, et al. Effect of the adjuvanted (AS03) A\/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series. BMJ Open. 2016;6:e009264.","journal-title":"BMJ Open."},{"key":"532_CR32","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1016\/j.vaccine.2016.05.016","volume":"34","author":"G Santos Dos","year":"2016","unstructured":"Dos Santos G, Haguinet F, Cohet C, Webb D, Logie J, Ferreira GLC, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series. Vaccine. 2016;34:3598\u2013606.","journal-title":"Vaccine."},{"key":"532_CR33","unstructured":"European Medicines Agency. Pandemrix. Procedural steps taken and scientific information after the authorisation. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000832\/WC500038125.pdf . Accessed 8 Feb 2017."},{"key":"532_CR34","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1016\/j.vaccine.2012.05.007","volume":"30","author":"CMAS Domingues","year":"2012","unstructured":"Domingues CMAS, de Oliveira WK, Brazilian Pandemic Influenza Vaccination Evaluation Team. Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010. Vaccine. 2012;30:4744\u201351.","journal-title":"Vaccine"},{"issue":"23","key":"532_CR35","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1016\/j.vaccine.2011.03.069","volume":"29","author":"Dietmar Walter","year":"2011","unstructured":"Walter D, B\u00f6hmer MM, an der Heiden M, Reiter S, Krause G, Wichmann O. Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009\/10\u2014results from thirteen consecutive cross-sectional surveys. Vaccine. 2011;29:4008\u201312.","journal-title":"Vaccine"},{"key":"532_CR36","unstructured":"Haut Conseil de la sant\u00e9 publique. Actualisation de l\u2019avis relatif aux recommandations sur les priorit\u00e9s sanitaires d\u2019utilisation des vaccins pand\u00e9miques dirig\u00e9s contre le virus grippal A(H1N1)v 2009."},{"key":"#cr-split#-532_CR37.1","unstructured":"8. Kumar D, Cordero E, Blumberg E, Limaye A, Levi M, Danziger-Isakov L, et al. A 5-year multicenter evaluation of seasonal influenza infection in transplant recipients. Am J Transplant. 2016"},{"key":"#cr-split#-532_CR37.2","unstructured":"9. 16(Suppl 3). http:\/\/www.atcmeetingabstracts.com\/abstract\/a-5-year-multicenter-evaluation-of-seasonal-influenza-infection-in-transplant-recipients\/ Accessed 8 Feb 2017."},{"key":"532_CR38","unstructured":"Willame C, Baril L, van den Bosch JH, Ferreira GL, Williams R, Rosillon D, et al. Importance of feasibility assessments before implementing non-interventional pharmacoepidemiological studies of vaccines: lessons learned and recommendations for future studies. Pharmacoepidemiol Drug Saf."},{"key":"532_CR39","unstructured":"NHS Blood and Transplant. Transplant activity in the UK, activity report 2009\/10."},{"key":"532_CR40","unstructured":"OPTN\/SRTR 2009, Annual report of the U.S. organ procurement and transplantation network and the scientific registry of transplant recipients: Transplant data 1999\u20132008. U.S. Department of Health and Human Services. 2009."},{"key":"532_CR41","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module IX\u2014signal management. EMA\/827661\/2011. 2012."},{"key":"532_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/pds.3502","volume":"23","author":"L Holle van","year":"2014","unstructured":"van Holle L, Bauchau V. Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm. Pharmacoepidemiol Drug Saf. 2014;23:178\u201385.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"532_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pds.3392","volume":"22","author":"L Holle Van","year":"2013","unstructured":"Van Holle L, Bauchau V. Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. Pharmacoepidemiol Drug Saf. 2013;22:477\u201387.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"532_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pds.3226","volume":"21","author":"L Holle Van","year":"2012","unstructured":"Van Holle L, Zeinoun Z, Bauchau V, Verstraeten T. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. Pharmacoepidemiol Drug Saf. 2012;21:603\u201310.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"532_CR45","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/pds.3397","volume":"22","author":"G Karimi","year":"2013","unstructured":"Karimi G, Star K, H\u00e4gg S, Nor\u00e9n GN. Time-to-onset in spontaneous reports: the possibility to detect the unexpected. Pharmacoepidemiol Drug Saf. 2013;22:556\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0532-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T12:01:37Z","timestamp":1719144097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0532-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0532-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,17]]},"assertion":[{"value":"17 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GlaxoSmithKline Biologicals SA took in charge all costs associated with the development and publication of the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ga\u00ebl Dos Santos reports he was employed by Business & Decision Life Sciences on behalf of GSK at the time of the study and is now employed by the GSK group of companies. Harry A. Seifert, Vincent Bauchau, Dominique M. Barbeau and Catherine Cohet are employees of the GSK group of companies. Ga\u00ebl Dos Santos, Harry A. Seifert, Vincent Bauchau, Dominique M. Barbeau and Catherine Cohet hold shares in the GSK group of companies as part of their employee remuneration. Vivek Shinde reports he was employed by GSK at the time of the signal investigation and is now employed by Novavax Vaccines, and holds shares in the GSK group of companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval and patient consent were not required during this investigation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}]}}